Biodelivery Sci Intl (BDSI) 2.58 $BDSI Endo's (ENDP)

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 8:21 AM

Biodelivery Sci Intl (BDSI) 2.58 $BDSI

Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), ANIP: 56.51 (-1.61), BMY: 75.28 (+1.20)

BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.58 (+0.07)

BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.58 (+0.07)

New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), ENL.TO: 22.79 (+0.99)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.58 (+0.07), INSY: 15.66 (+0.33), AGIO: 42.75 (+0.12), GNCA: 4.45 (+0.11)

BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.58 (+0.07)

BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.58 (+0.07), HSKA: 43.52 (+2.33), ANIP: 56.51 (-1.61), COLL: 12.74 (+0.24)

Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.58 (+0.07)

Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.58 (+0.07), COLL: 12.74 (+0.24)

BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.58 (+0.07), COLL: 12.74 (+0.24)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08)

BioDelivery's (BDSI) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Tue May 10, 7:50AM CDT
BioDelivery's first-quarter 2016 loss of 36 cents per share came in line with consensus estimates.
BDSI: 2.58 (+0.07)

BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
-- Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017
BDSI: 2.58 (+0.07)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.58 (+0.07), INO: 9.11 (+0.03), VVUS: 1.18 (+0.02), TEVA: 50.89 (+0.37), ARNA: 1.70 (+0.06), PBYI: 34.88 (+2.73)

Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 29.35 (+0.23), BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), JAZZ: 139.88 (+1.40)

BioDelivery Sciences Announces Acceptance of an Abstract to the International Conference on Opioids on the Impact of a State Formulary Conversion to BUNAVAIL
PR Newswire - Fri Apr 29, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the acceptance of an abstract for presentation at the International Conference on Opioids, which takes place June 5-7, 2016 in Boston, Massachusetts. The abstract entitled, Reduced Buprenorphine/Naloxone Prescriptions Dispensed in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail: Implications for Potential Diversion, has been accepted for a poster presentation to take place on Monday, June 6. Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author, will present the data.
BDSI: 2.58 (+0.07)

U.S. Patent and Trademark Office Upholds the Validity of MonoSol Rx's US Patent No. 8,765,167 in the Face of Multiple Inter Partes Review Challenges Brought by BioDelivery Sciences International, Inc. (BDSI)
GlobeNewswire - Thu Apr 07, 7:30AM CDT
MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm(R) drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Patent and Trademark Office (USPTO) has upheld the validity of all challenged claims in U.S. Patent No. 8,765,167 (the '167 patent). The challenges to the '167 patent were asserted in four Inter Partes Review (IPR) proceedings brought by BioDelivery Sciences International, Inc. (Nasdaq:BDSI) ("BDSI"

against MonoSol Rx.
BDSI: 2.58 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

TKO's Bold $2B All-Cash Move for SVC's Hotels

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

ONLYOFFICE 10.0 Boosts AI and Security Features

A Fresh Look at ONLYOFFICE 10.0's Game-Changing Update Outta the gates swinging, ONLYOFFICE dropped their latest 10.0 update. This one ain't just your average software facelift—it's packing some serious heat with AI enhancements, brand spanking new modular apps, and beefed-up security features that'll make anyone dealing with sensitive data breathe a little easier. AI...

Duke Energy Braces for Isaias: Key Prep Steps Ahead

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

Phoenix Scholar Examines AI and Institutional Trust

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

A Shot at Adventure Without Opening Your Wallet Let me tell you, Korea's got a way of sweeping folks off their feet with a little something for everyone—from a foodie’s paradise to history buff heaven. The Korea Tourism Organization's (KTO) New York Office is lighting up the stage with a slick offer: enter a quiz on their website and you might just be jetting off to...

ODL’s Impact Door System Wins 2026 Editors' Pick

Award-Winning Entry: ODL's Latest Triumph In a world where first impressions count, ODL, Inc. sure knows how to leave a mark. Their Impact Rated Fiberglass Entry System with Keystone Frame Technology snagged a notable spot in the 2026 Best of Products Awards by Architect's Newspaper. Let me tell you, in the building biz, accolades like these are no small potatoes. To get...

Amap, Sands China Unleash Tutu Robots for Resort Duty

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

NOARK: Powering Data Centers with Global-Local Approach

The High-Stakes Race for Data Center Power These days, if you're not talking about data centers, you're probably a step behind the curve. AI's explosive growth is pushing data center developments across North America like never before. Larger campuses, hefty power densities—it's all happening at a pace that's got everyone scrambling. For folks like NOARK Electric, this...